Increased small low-density lipoprotein particle number - A prominent feature of the metabolic syndrome in the Framingham Heart Study

被引:237
作者
Kathiresan, S
Otvos, JD
Sullivan, LM
Keyes, MJ
Schaefer, EJ
Wilson, PWF
D'Agostino, RB
Vasan, RS
Robins, SJ
机构
[1] NHLBI, Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA
[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02115 USA
[3] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA
[4] MIT, Cambridge, MA USA
[5] LipoSci Inc, Raleigh, NC USA
[6] Boston Univ, Dept Math, Boston, MA 02215 USA
[7] Boston Univ, Stat & Consulting Unit, Boston, MA 02215 USA
[8] Tufts Univ, Sch Med, Lipid Res Lab, Boston, MA 02111 USA
[9] Med Univ S Carolina, Dept Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA
关键词
cholesterol; lipids; lipoproteins; metabolic syndrome X; risk factors;
D O I
10.1161/CIRCULATIONAHA.105.567107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Levels of LDL cholesterol (LDL-C) are frequently not elevated in individuals with the metabolic syndrome (MetSyn). However, the atherogenic potential of LDL may depend on the number and size of LDL particles in addition to the cholesterol content of LDL. Methods and Results-We examined the sex-specific cross-sectional relations of small LDL particle number ( determined by nuclear magnetic resonance spectroscopy) to the presence of MetSyn and its components in 2993 Framingham Heart Study participants ( mean age, 51 years; 53% women) without cardiovascular disease (CVD) and the relations of small LDL particle number to CVD incidence in people with MetSyn. The MetSyn (>= 3 of 5 traits as defined by the National Cholesterol Education Adult Treatment Panel III) was present in 27% of men and 17% of women. In both sexes, small LDL particle number increased from 0 to 5 MetSyn traits, a pattern partly accounted for by strong correlations between small LDL particle number and serum triglycerides (r=0.61, P < 0.0001) and HDL-C (r=-0.55, P < 0.0001). Compared with participants without the MetSyn, those with the MetSyn had a higher CVD event rate. However, among participants with the MetSyn, CVD rates were similar for groups with an elevated versus a lower number of small LDL particles ( defined by the sex-specific median). Conclusions-Small LDL particle number is elevated in the MetSyn, increases with the number of MetSyn components, and most prominently is correlated with triglycerides and HDL-C. Whereas increased small LDL particle number identified the MetSyn with high sensitivity, a higher small LDL particle number was not associated with greater CVD event rates in people with the MetSyn.
引用
收藏
页码:20 / 29
页数:10
相关论文
共 44 条
[1]  
[Anonymous], 2005, The IDF consensus worldwide definition of the metabolic syndrome
[2]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[3]   Metabolic origins and clinical significance of LDL heterogeneity [J].
Berneis, KK ;
Krauss, RM .
JOURNAL OF LIPID RESEARCH, 2002, 43 (09) :1363-1379
[4]   Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system [J].
Bjornheden, T ;
Babyi, A ;
Bondjers, G ;
Wiklund, O .
ATHEROSCLEROSIS, 1996, 123 (1-2) :43-56
[5]   Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women [J].
Blake, GJ ;
Otvos, JD ;
Rifai, N ;
Ridker, PM .
CIRCULATION, 2002, 106 (15) :1930-1937
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
Contois JH, 1996, CLIN CHEM, V42, P515
[8]   Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study [J].
Dekker, JM ;
Girman, C ;
Rhodes, T ;
Nijpels, G ;
Stehouwer, CDA ;
Bouter, LM ;
Heine, RJ .
CIRCULATION, 2005, 112 (05) :666-673
[9]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[10]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422